Skip to main content
Bone Research logoLink to Bone Research
. 2022 Nov 15;10:64. doi: 10.1038/s41413-022-00238-5

Correction To: Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss

Chen Kan 1,2,3,#, Jiazhao Yang 4,#, Haitao Fan 5,#, Yuanjuan Dai 1, Xingxing Wang 1, Rui Chen 1, Jia Liu 1, Xiangyue Meng 1, Wei Wang 1, Guiling Li 1, Jiao Zhou 1, Ya Zhang 1, Wanbo Zhu 4, Shiyuan Fang 4, Haiming Wei 2,3, Hong Zheng 1,, Siying Wang 1,, Fang Ni 2,3,
PMCID: PMC9663427  PMID: 36376272

Correction to: Bone Research 10.1038/s41413-022-00232-x, published online 27 October 2022

Following publication of this article1, it is noticed that a sentence “FetA was characterized as a decoy receptor of transforming growth factor beta (TGF-β)/BMP, suggesting that FetA could be useful to inhibit and/or prevent TGF-β/BMP-induced diseases, including heterotopic ossification61,62,63,64.” needs to be inserted in the section DISCUSSION. References 61–64 are also added.

In addition, the reference number “2019YFA0801801” should be changed to “2019YFA0801800” in the section ACKNOWLEDGEMENTS.

The original article1 was updated.

Footnotes

These authors contributed equally: Chen Kan, Jiazhao Yang, Haitao Fan.

Contributor Information

Hong Zheng, Email: zhenghong@ahmu.edu.cn.

Siying Wang, Email: sywang@ahmu.edu.cn.

Fang Ni, Email: fangni@ustc.edu.cn.

Reference

  • 1.Kan C, et al. Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss. Bone Res. 2022;10:62. doi: 10.1038/s41413-022-00232-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Bone Research are provided here courtesy of Nature Publishing Group

RESOURCES